Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›Invesco›SBIO

SBIO

Invesco NASDAQ Biotech UCITS ETF

Passive ETF Equity

The SBIO Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: NASDAQ Biotechnology Index. This ETF provides synthetic exposure, by owning its shares you earn the return of the index indirectly through the use of derivatives or a swap (i.e. a contract with a financial institution which delivers the return of the index). The dividend policy is capitalization.

$67.51

-$0.44 (-0.65%) today

8:12 AM 07/23/26 Open

1D price range

$67.36$67.62

52W price range

$45.56$71.43

YTD Perf.

+14.93%

YTD Flows

Annualized volatility

Fund AuM

€428M

Share class AuM

€428M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

IE00BQ70R696

TER

0.4%

Inception date

11/7/2014

Issuer

Invesco

Benchmark

NASDAQ Biotechnology Index

Replication method

Dividend policy

Capitalization

Compare similar ETFs

No content available for this fund

API

PerformanceDec 31, 2025 - Jul 21, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 06/30/26

Healthcare

99.83%

Unavailable

0.15%

Latest SBIO news

No content available for this fund

FAQ about SBIO

SBIO is a Passive ETF. This ETF provides exposure to US Equities.

SBIO tracks the NASDAQ Biotechnology Total Return Index - USD, through a unfunded swap replication method.

SBIO carries a total expense ratio (TER) of 0.4%, indicating the annual cost for holding the fund.

SBIO was introduced to the market on November 7, 2014. It trades on Netherlands, among other exchanges

Invesco NASDAQ Biotech UCITS ETF, SBIO, is provided by Invesco. Learn more about Invesco here.

SBIO oversees €428M in assets as of July 21, 2026.

SBIO follows a capitalizing, meaning it reinvests income within the fund.

As of June 30, 2026, SBIO has significant geographic allocations in USA, Netherlands and United Kingdom.

As of June 30, 2026, SBIO focuses largely on Healthcare.

As of June 30, 2026, SBIO holds 251 positions in its portfolio, with 49.07% of assets concentrated in its top 15 holdings.

As of June 30, 2026, SBIO top three holdings include Vertex Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc..

The base currency of SBIO is USD.

Top 10 holdings

Data as of 06/30/26

Vertex Pharmaceuticals, Inc.

8.13%

Amgen, Inc.

7.87%

Gilead Sciences, Inc.

6.88%

Regeneron Pharmaceuticals, Inc.

4.49%

Alnylam Pharmaceuticals, Inc.

2.81%

Revolution Medicines, Inc.

2.78%

Biogen, Inc.

2.23%

Moderna, Inc.

1.94%

Illumina, Inc.

1.86%

argenx SE

1.79%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

Invesco NASDAQ Biotech UCITS ETF

FAQ about SBIO

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US